FEMY vs XWEL vs CODA vs SKIN vs SSKN

For growth investors, Femasys Inc.

(FEMY) is the stronger pick with 40. 8% revenue growth year-over-year, versus -13. 8% for XWELL, Inc. (XWEL). Coda Octopus Group, Inc. (CODA) offers the better valuation at 32. 7x trailing P/E (22. 8x forward), making it the more compelling value choice. Analysts rate Coda Octopus Group, Inc. (CODA) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Coda Octopus Group, Inc.

(CODA) delivered a total return of +55. 9%, compared to -99. 0% for STRATA Skin Sciences, Inc. (SSKN). Over 10 years, the gap is even starker: CODA returned +861. 1% versus XWEL's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), STRATA Skin Sciences, Inc.

(SSKN) is the lower-risk stock at -0. 38β versus The Beauty Health Company's 1. 71β — meaning SKIN is approximately -546% more volatile than SSKN relative to the S&P 500. On balance sheet safety, Coda Octopus Group, Inc. (CODA) carries a lower debt/equity ratio of 1% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Femasys Inc.

(FEMY) is pulling ahead at 40. 8% versus -13. 8% for XWELL, Inc. (XWEL). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to -38. 8% for XWELL, Inc.. Over a 3-year CAGR, FEMY leads at 23. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Coda Octopus Group, Inc.

(CODA) is the more profitable company, earning 15. 5% net margin versus -812. 3% for Femasys Inc. — meaning it keeps 15. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CODA leads at 17. 1% versus -767. 0% for FEMY. At the gross margin level — before operating expenses — CODA leads at 66. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for SKIN: 124.

1% to $1. 30.

In this comparison, XWEL (3.

2% yield) pays a dividend. FEMY, CODA, SKIN, SSKN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, STRATA Skin Sciences, Inc.

(SSKN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 38)). The Beauty Health Company (SKIN) carries a higher beta of 1. 71 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SSKN: -99. 6%, SKIN: -94. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (FEMY (Healthcare) and XWEL (Consumer Cyclical) and CODA (Industrials) and SKIN (Consumer Defensive) and SSKN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: FEMY is a small-cap high-growth stock; XWEL is a small-cap income-oriented stock; CODA is a small-cap high-growth stock; SKIN is a small-cap quality compounder stock; SSKN is a small-cap quality compounder stock. XWEL pays a dividend while FEMY, CODA, SKIN, SSKN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.